Bridgepoint / Bridgepoint to acquire PharmaZell

PharmaZell, a leading independent manufacturer of niche active pharmaceutical ingredients (APIs), was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum.

PharmaZell is a market leader in the highly resilient and
specialty API market where it has a diversified portfolio of over
70 APIs, and enjoys leading industry positions in several products
that treat respiratory, inflammatory and liver diseases driven by
changing lifestyle habits. Many of the Company’s products require
special handling procedures and/or technologies. Headquartered in
Raubling (near Munich), PharmaZell operates four state-of-the-art
production and R&D sites in Germany, Italy and India with over
900 employees globally.

The global market for small molecule APIs is estimated at over
$70bn and growing continuously, driven by rising health standards
and increasing drug consumption in emerging markets. In addition,
the trend to outsourcing continues driven by cost optimisation and
streamlining initiatives by the pharma majors.

Commenting on the transaction, PharmaZell CEO Dr. Oliver
Bolzern, said: “We welcome Bridgepoint as our new shareholder. In
Bridgepoint we have found a partner who understands our business
and who will work with us to help us realise our ambitions for
further growth.”

Related:  Bridgepoint / BDC to invest in Reassured

Carsten Kratz, Senior Partner of Bridgepoint, Frankfurt
commented: “PharmaZell represents an exciting opportunity to invest
in a robust platform with an experienced management team and a
high-quality customer base in the growing and non-cyclical pharma
market.  With a strong track record of growth, the company
also offers the prospect of further new products and with
Bridgepoint will have the resources and reach to further develop
selective acquisition opportunities.”

Guido Prehn, Managing Partner at DPE Deutsche Private Equity,
added: “Since our investment into PharmaZell in early 2014, the
company has generated double-digit annual growth at
industry-leading margins, almost doubling in size. It has been a
fantastic partnership with management and we are truly happy to
have found in Bridgepoint a new growth-focused home for this great

Advisers involved in this transaction included:

For Bridgepoint: Alantra (M&A), HSBC (M&A), Freshfields
(legal), EY (financial & tax), BCG (commercial)

For DPE: Rothschild (M&A), Latham & Watkins (legal),
Deloitte (financial & tax), L.E.K. (commercial) as well as ERM

See More News From: